Sichuan Goldstone Asia Pharmaceutical Inc. (300434.SZ)
CNY 8.73
(-0.8%)
CNY 8.73
(-0.8%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.2 Billion | 1.24 Billion | 1.05 Billion | 777.29 Million | 1 Billion | 970.71 Million |
| Cost of Revenue | 466.91 Million | 480.49 Million | 455.72 Million | 358.4 Million | 357.43 Million | 330.71 Million |
| Gross Profit | 742.28 Million | 762.1 Million | 597.78 Million | 418.88 Million | 648.16 Million | 640 Million |
| Operating Expenses | 564.08 Million | 469.38 Million | 467.93 Million | 412.97 Million | 466.09 Million | 450.23 Million |
| Selling, General and Administrative Expenses | 428.94 Million | 304.57 Million | 301.3 Million | 260.14 Million | 302.04 Million | 298 Million |
| Research and Development Expenses | 50.01 Million | 39.18 Million | 37.45 Million | 27.83 Million | 28.54 Million | 27.92 Million |
| Other Expenses | 85.12 Million | -1.42 Million | 4.55 Million | 2.85 Million | -512.98 Thousand | -445.43 Thousand |
| Cost and Expenses | 1.03 Billion | 949.87 Million | 923.65 Million | 771.38 Million | 823.53 Million | 780.94 Million |
| Operating Income | 177.93 Million | 291.96 Million | 88.98 Million | -667.94 Million | 160.57 Million | 189.27 Million |
| Interest Expense | 966.1 Thousand | 460.37 Thousand | 15.47 Thousand | 170.25 Thousand | 947.45 Thousand | 2.45 Million |
| Income Tax Expense | 56.3 Million | 77.49 Million | 27.43 Million | 19.38 Million | 34.19 Million | 35.51 Million |
| Earnings before Tax | 177.01 Million | 290.53 Million | 93.53 Million | -665.09 Million | 160.05 Million | 188.83 Million |
| Net Income | 126.19 Million | 218.78 Million | 66.48 Million | -687.65 Million | 120.33 Million | 149.15 Million |
| Earnings Per Share Basic | 0.31 | 0.54 | 0.17 | -1.71 | 0.30 | 0.37 |
| Earnings Per Share Diluted | 0.31 | 0.54 | 0.17 | -1.71 | 0.30 | 0.37 |
| Weighted Average Shares Outstanding | 407.09 Million | 401.74 Million | 401.74 Million | 401.74 Million | 401.74 Million | 401.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 407.09 Million | 401.74 Million | 401.74 Million | 401.74 Million | 401.74 Million | 403.11 Million |
| Gross Margin | 0.61 | 0.61 | 0.57 | 0.54 | 0.64 | 0.66 |
| EBIT Margin | 0.23 | 0.30 | 0.20 | 0.12 | 0.27 | 0.28 |
| Profit Margin | 0.10 | 0.18 | 0.06 | -0.88 | 0.12 | 0.15 |
| EBITDA | 272.1 Million | 382.32 Million | 180.67 Million | -572.48 Million | 242.69 Million | 275.79 Million |
| Earnings Before Tax Margin | 0.15 | 0.23 | 0.08 | -0.86 | 0.16 | 0.19 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 234.71 Million | 159.14 Million | 357.48 Million | 1.2 Billion | 382.13 Million | 193.33 Million |
| Cost of Revenue | 112.43 Million | 84.33 Million | 140.82 Million | 466.91 Million | 137.56 Million | 100.29 Million |
| Gross Profit | 122.27 Million | 74.81 Million | 216.66 Million | 742.28 Million | 244.56 Million | 93.04 Million |
| Operating Expenses | 96.68 Million | 119.29 Million | 102.68 Million | 494.39 Million | 173.2 Million | 112.38 Million |
| Selling, General and Administrative Expenses | 192.98 Million | 47.68 Million | 94.2 Million | - | 25.24 Million | 153.6 Million |
| Research and Development Expenses | 10.17 Million | 11.36 Million | 8.5 Million | - | 9.99 Million | 12.15 Million |
| Other Expenses | -106.47 Million | -4.52 Million | 22.13 Thousand | -921.83 Thousand | -1.12 Million | -164.49 Thousand |
| Cost and Expenses | 209.11 Million | 203.62 Million | 243.5 Million | 961.31 Million | 310.76 Million | 212.68 Million |
| Operating Income | 23.72 Million | -49.73 Million | 113.98 Million | 177.93 Million | 6.31 Million | -18.67 Million |
| Interest Expense | 302.4 Thousand | 473.42 Thousand | 232.9 Thousand | 671.74 Thousand | -1.72 Million | 649.02 Thousand |
| Income Tax Expense | 3.48 Million | -2.69 Million | 26.02 Million | 56.3 Million | 19.97 Million | -597.15 Thousand |
| Earnings before Tax | 21.39 Million | -54.26 Million | 115.56 Million | 177.01 Million | 5.18 Million | -18.84 Million |
| Net Income | 18.92 Million | -50.61 Million | 89.81 Million | 126.19 Million | -12.58 Million | -16.94 Million |
| Earnings Per Share Basic | 0.05 | -0.13 | 0.22 | - | -0.03 | -0.04 |
| Earnings Per Share Diluted | 0.05 | -0.13 | 0.22 | - | -0.03 | -0.04 |
| Weighted Average Shares Outstanding | 401.74 Million | 401.74 Million | 401.74 Million | 407.09 Million | 438.83 Million | 401.74 Million |
| Weighted Average Shares Outstanding (Diluted) | 401.74 Million | 401.74 Million | 401.74 Million | 407.09 Million | 438.82 Million | 401.74 Million |
| Gross Margin | 0.52 | 0.47 | 0.61 | 0.61 | 0.64 | 0.48 |
| EBIT Margin | 0.09 | -0.32 | 0.32 | - | 0.18 | -0.10 |
| Profit Margin | 0.08 | -0.32 | 0.25 | 0.10 | -0.03 | -0.09 |
| EBITDA | 21.69 Million | -50.5 Million | 115.88 Million | - | 67.79 Million | -20.21 Million |
| Earnings Before Tax Margin | 0.10 | -0.31 | 0.32 | 0.15 | 0.02 | -0.10 |
DYAN
VNT
CHCLY
6332
IDMO
BO